Genmab A/S is trading at 197.58 as of the 30th of March 2025. This is a 0.73 percent down since the beginning of the trading day. The stock's lowest day price was 197.58. Genmab A/S has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 30th of December 2024 and ending today, the 30th of March 2025. Click here to learn more.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on OTC Exchange in the United States. The company has 65.96 M outstanding shares. More on Genmab AS
Genmab AS [GNMSF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Large-Cap' category with a current market capitalization of 26.78 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab A/S's market, we take the total number of its shares issued and multiply it by Genmab A/S's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Genmab A/S classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 65.96 M outstanding shares.
Genmab AS has accumulated about 21.61 B in cash with 2.23 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 330.53.
Check Genmab A/S Probability Of BankruptcyOwnership AllocationGenmab AS has a total of 65.96 Million outstanding shares. 30% of Genmab A/S outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Genmab Ownership Details
Our tools can tell you how much better you can do entering a position in Genmab A/S without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Portfolio Manager Now
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Additional Information and Resources on Investing in Genmab Pink Sheet
When determining whether Genmab A/S offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab A/S's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Please note, there is a significant difference between Genmab A/S's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab A/S is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab A/S's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.